AN ACT

To enact R.S. 40:2018.3.1, relative to Medicaid coverage for sickle cell disease; to require an annual review of available treatments for sickle cell disease; to require an assessment of Medicaid coverage for sickle cell treatments; to provide for public input; to provide for annual reporting by the Louisiana Department of Health; to provide for a short title; and to provide for related matters.

Be it enacted by the Legislature of Louisiana:

Section 1. R.S. 40:2018.3.1 is hereby enacted to read as follows:

§2018.3.1. Annual review of Medicaid coverage for sickle cell disease

A. The Louisiana Department of Health shall conduct an annual review of all medications and forms of treatment for sickle cell disease and services for enrollees with a diagnosis of sickle cell disease that are eligible for coverage under the Louisiana Medicaid program. The department shall determine if the available covered medications, treatments, and services are adequate to meet the needs of enrollees with a diagnosis of sickle cell disease and whether the department should seek to add additional medications, treatments, or services.

B. When conducting the annual review required by Subsection A of this
Section, the Louisiana Department of Health shall solicit and consider input from the general public with specific emphasis on attempting to receive input from persons or groups with knowledge and experience in the area of sickle cell disease treatment.

D. On or before January 15, 2023, and on or before January 15 each year thereafter, the Louisiana Department of Health shall submit a report to the Senate Committee on Finance, the House Committee on Appropriations, and the Senate and House committees on health and welfare that details the department's findings from the annual review required by this Section, as well as any recommendations to the legislature based upon those findings. The department shall publish the annual report required by this Subsection on its website in a manner accessible by the general public.

Section 2. This Act shall be known and may be cited as "Lorri Burgess' Law".

The original instrument and the following digest, which constitutes no part of the legislative instrument, were prepared by Brandi Cannon.

D I G E S T

SB 298 Original 2022 Regular Session Barrow

Proposed law requires the La. Dept. of Health (LDH) to conduct an annual review of all medications and forms of treatment for sickle cell disease and services for enrollees with a diagnosis of sickle cell disease that are eligible for coverage under the La. Medicaid program. Proposed law requires LDH to determine if the available covered medications, treatments, and services are adequate to meet the needs of enrollees or whether LDH should seek to add additional medications, treatments, or services.

Proposed law requires, on or before January 15 of each year, the La. Dept. of Health to submit a report to the Senate Committee on Finance, the House Committee on Appropriations, and the Senate and House committees on health and welfare that details LDH's findings from the annual review, as well as any recommendations to the legislature based upon those findings. Proposed law also requires LDH to publish the annual report on its website in a manner accessible by the general public.

Proposed law shall be known as "Lorri Burgess' Law".

Effective August 1, 2022.

(Adds R.S. 40:2018.3.1)